New Quick-Acting Ebola Vaccine Offers Complete Protection with just One Dose

by Bidita Debnath on  April 10, 2015 at 12:40 AM Tropical Disease News   - G J E 4
The University of Texas scientists have developed a quick and safe Ebola vaccine, that shows its effect against the Ebola strain with just one dose.
New Quick-Acting Ebola Vaccine Offers Complete Protection with just One Dose
New Quick-Acting Ebola Vaccine Offers Complete Protection with just One Dose

Created by an interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc., the vaccine, effective against Ebola Zaire with a single dose in a nonhuman primate model, has been undergoing testing in the Galveston National Laboratory, the only fully operational Biosafety Level 4 laboratory on an academic campus in the U.S.

This new vaccine employs a virus not harmful to humans called vesicular stomatitis virus that had a part of the Ebola virus inserted into it. This "Trojan horse" vaccine safely triggered an immune response against Ebola Zaire.

UTMB professor Thomas Geisbert said that the findings may pave the way for the identification and manufacture of safer, single dose, high efficiency vaccines to combat current and future Ebola outbreaks.

To address any possible safety concerns associated with this vaccine, the team developed two next generation candidate vaccines that contain further weakened forms of the vaccine. Both of these vaccines produced an approximately ten-fold lower level of virus in the blood compared to the first generation vaccine.

Chief Scientific Officer, John Eldridge, said that the findings show that their candidate vaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola virus.

Both weakened vaccines have features of the Mayinga strain of Ebola virus, as do most other candidate Ebola Zaire vaccines currently under evaluation. The original 1976 Mayinga strain and the new West African Makona strain are quite similar. The researchers said it was important to test their candidate vaccines on the Makona strain to ensure that even small differences between the strains didn't impact the effectiveness of the vaccine.

The findings are published in Nature.

Source: ANI

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like